Metagen Therapeutics Closes 1.7 Billion Yen Series A Financing
Summary
Metagen Therapeutics, a Tsuruoka, Japan-based company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, completed its Series A funding in 2 rounds, raising a total of 1.7 billion yen. Sparx Asset Management, Nippon Venture Capital, Mizuho Capital and SMBC Venture Capital have joined the 1st round investors of JIC Venture Growth Investments, a type of sovereign wealth fund in Japan, JAFCO, Japan’s largest venture capital company, Fast Track Initiative and Keio Innovation Initiative. With the closing of the 2nd round, Metagen Therapeutics has raised a total amount of 1.93 billion yen since its inception. Promotion of basic and clinical research for clinical application of FMT (such as joint research related to immune checkpoint inhibitors) Founded by researchers of Juntendo University, Keio University and Tokyo Institute of Technology in 2020 and led by President & CEO Taku Nakahara, Metagen Therapeutics is a biotech startup focused on drug discovery and medical business through microbiota therapeutics. It aims for social impact through medical care and drug discovery.